

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

Original Issue Date (Created):	<b>7/1/2002</b>
Most Recent Review Date (Revised):	<b>3/17/2020</b>
<b>Effective Date:</b>	<b>8/1/2020</b>

[POLICY RATIONALE](#)  
[DISCLAIMER](#)  
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)  
[DEFINITIONS](#)  
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)  
[BENEFIT VARIATIONS](#)  
[REFERENCES](#)

**I. POLICY**

[TOP](#)

Carotid angioplasty with associated stenting and embolic protection may be considered **medically necessary** in patients with:

- 50%–99% stenosis (North American Symptomatic Carotid Endarterectomy Trial [NASCET] measurement); **and**
- Symptoms of focal cerebral ischemia (transient ischemic attack or monocular blindness) in previous 120 days, symptom duration less than 24 hours, or nondisabling stroke; **and**
- Anatomic contraindication for carotid endarterectomy (such as prior radiation treatment or neck surgery, lesions surgically inaccessible, spinal immobility, or tracheostomy).

Carotid angioplasty with associated stenting and embolic protection is considered **investigational** for all other indications, including but not limited to, patients with carotid stenosis who are suitable candidates for carotid endarterectomy (CEA) and patients with carotid artery dissection. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Carotid angioplasty without associated stenting and embolic protection is considered **investigational** for all indications, including but not limited to, patients with carotid stenosis who are suitable candidates for carotid endarterectomy and patients with carotid artery dissection. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

**POLICY GUIDELINES**

The intent of the second investigational policy statement is that carotid angioplasty with embolic protection but without stenting is investigational. There may be unique situations where the original intent of surgery was to perform carotid angioplasty with stenting and embolic protection but anatomic or other considerations prohibited placement of the stent.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

### II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below.

**FEP PPO:** Refer to FEP Medical Policy Manual MP-7.01.68, Extracranial Carotid Stenting. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

### III. DESCRIPTION/BACKGROUND

[TOP](#)

Combined with optimal medical management, carotid angioplasty with or without stenting has been evaluated as an alternative to carotid endarterectomy (CEA). Carotid artery stenting (CAS) involves the introduction of coaxial systems of catheters, microcatheters, balloons, and other devices. The procedure is most often performed through the femoral artery, but a transcervical approach can also be used to avoid traversing the aortic arch. The procedure typically takes 20 to 40 minutes. Interventionalists almost uniformly use an embolic protection device (EPD) designed to reduce the risk of stroke caused by thromboembolic material dislodged during CAS. EPDs can be deployed proximally (with flow reversal) or distally (using a filter). Carotid angioplasty rarely is performed without stent placement.

The proposed advantages of CAS over CEA include:

- General anesthesia is not used (although CEA can be performed under local/regional anesthesia)
- Cranial nerve palsies are infrequent sequelae (although almost all following CEA resolve over time)
- Simultaneous procedures may be performed on the coronary and carotid arteries.

### REGULATORY STATUS

A number of CAS and EPDs have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval (PMA) or the 510(k) process. Examples are provided in Table 1.

**Table 1. FDA-Approved Carotid Artery Stents and Embolic Protection Devices**

Manufacturer	Stents and Devices	PMA/510(k) Date
<b>Guidant, now Abbott Vascular</b>	Acculink™ and RX Acculink™ carotid stents	Aug 2004

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

<b>Guidant, now Abbott Vascular</b>	AccUNET™ and RX AccUNET™ cerebral protection filters	Aug 2004
<b>Abbott Vascular</b>	Xact® RX carotid stent system	Sep 2005
<b>Abbott Vascular</b>	Emboshield® embolic protection system	Sep 2005
<b>Cordis Corp.</b>	Precise® nitinol carotid stent system	Sep 2006
<b>Cordis Corp.</b>	AngioGuard™ XP and RX emboli capture guidewire systems	Sep 2006
<b>EndoTex Interventional Systems</b>	NexStent® carotid stent over-the-wire and monorail delivery systems	Oct 2006
<b>Boston Scientific</b>	FilterWire EZ™ embolic protection system	Oct 2006
<b>ev3, Arterial Evolution Technology</b>	Protégé® Rx and SpideRx®	Jan 2007
<b>Boston Scientific</b>	Carotid Wallstent®	Oct 2008
<b> Gore</b>	GORE® Flow Reversal System	Feb 2009
<b> Gore</b>	GORE® Embolic Filter	May 2011
<b>Medtronic/Invatec</b>	Mo.Ma® Ultra Proximal Cerebral Protection Device	Oct 2009
<b>Silk Road Medical</b>	ENROUTE™ Transcarotid Stent System and ENROUTE Transcarotid Neuroprotection System	May 2015

FDA: Food and Drug Administration; PMA: premarket approval.

Each FDA-approved carotid stent is indicated for combined use with an EPD to reduce risk of stroke in patients considered to be at increased risk for periprocedural complications from carotid endarterectomy (CEA) who are symptomatic with greater than 50% stenosis, or asymptomatic with greater than 80% stenosis degree of stenosis assessed by ultrasound or angiogram with computed tomography angiography also sometimes used. Patients are considered at increased risk for complications during CEA if affected by any item from a list of anatomic features and comorbid conditions included in each stent system’s Information for Prescribers.

The RX Acculink Stent System™ is also approved for use in conventional risk patients (not considered at increased risk for complications during CEA) with symptoms and 70% or more stenosis by ultrasound or 50% or more stenosis by angiogram, and asymptomatic patients with 70% or more stenosis by ultrasound or 60% or more stenosis by angiogram.

The FDA-approved stents and EPDs differ in the deployment methods used once they reach the target lesion, with the rapid exchange devices designed for more rapid stent and filter expansion. The FDA has mandated postmarketing studies for EPDs, including longer follow-up for patients already reported to the FDA and additional registry studies, primarily to compare outcomes as a function of clinician training and facility experience. Each manufacturer’s system is available in various configurations (e.g., straight or tapered) and sizes (diameters and lengths) to match the vessel lumen that will receive the stent.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

In 2015, the ENROUTE™ Transcarotid Neuroprotection System was cleared for marketing by the FDA through the 510(k) process. ENROUTE™ is a flow reversal device designed to be placed via direct carotid access.

FDA product codes: NIM (stents) and NTE (EPDs).

**IV. RATIONALE**

[TOP](#)

**Summary of Evidence**

For individuals who have carotid artery stenosis who receive CAS, the evidence includes randomized controlled trials and systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. A substantial body of RCT evidence has compared outcomes of CAS with CEA for symptomatic and asymptomatic patients with carotid stenosis. The evidence does not support the use of CAS in carotid artery disease for the average-risk patient, because early adverse events are higher with CAS and long-term outcomes are similar between the 2 procedures. Data from RCTs and large database studies have established that the risk of death or stroke with CAS exceeds the threshold considered acceptable to indicate overall benefit from the procedure. Therefore, for patients with carotid stenosis who are suitable candidates for CEA, CAS does not improve health outcomes. The evidence is sufficient to determine that the technology is unlikely to improve the net health outcome.

**V. DEFINITIONS**

[TOP](#)

**ANGIOPLASTY** is an endovascular procedure that reopens narrowed blood vessels and restores forward blood flow.

**STENT** is a material or device used to hold tissue in place, to maintain open blood vessels, or to provide a support for a graft or anastomosis while healing is taking place.

**CAROTID ARTERY** pertains to the right and left common carotid arteries, which form the principal supply to the head and neck.

**CAROTID ENDARTERECTOMY** is a surgical technique for removing intra-arterial obstructions of the proximal cervical portion of the internal carotid artery. The technique reduces the risk of stroke when it is performed on a patient with moderate or severe stenosis of the artery, with or without a history of transient ischemic attacks.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

**VI. BENEFIT VARIATIONS**

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

**VII. DISCLAIMER**

[TOP](#)

*Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital BlueCross' Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

**VIII. CODING INFORMATION**

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Covered when medically necessary:**

<b>CPT Codes ®</b>							
37217	37218						

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

<b>ICD-10-CM Diagnosis Code</b>	<b>Description</b>
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

I65.21	Occlusion and stenosis of right carotid artery
I65.22	Occlusion and stenosis of left carotid artery
I65.23	Occlusion and stenosis of bilateral carotid arteries

**IX. REFERENCES**

[TOP](#)

1. *Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. Aug 15 1991;325(7):445-453. PMID 1852179*
2. *MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet. May 25 1991;337(8752):1235-1243. PMID 1674060*
3. *Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA. Dec 18 1991;266(23):3289-3294. PMID 1960828*
4. *Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. May 10 1995;273(18):1421-1428. PMID 7723155*
5. *Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. May 9 1998;351(9113):1379-1387. PMID 9593407*
6. *Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. Nov 12 1998;339(20):1415-1425. PMID 9811916*
7. *Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. May 8 2004;363(9420):1491-1502. PMID 15135594*
8. *Marquardt L, Geraghty OC, Mehta Z, et al. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke. Jan 2010;41(1):e11-17. PMID 19926843*
9. *Naylor AR, Bell PR. Treatment of asymptomatic carotid disease with stenting: con. Semin Vasc Surg. Jun 2008;21(2):100-107. PMID 18565417*
10. *Brott TG, Hobson RW, 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. Jul 1 2010;363(1):11-23. PMID 20505173*
11. *De Rango P, Brown MM, Leys D, et al. Management of carotid stenosis in women: consensus document. Neurology. Jun 11 2013;80(24):2258-2268. PMID 23751919*
12. *Jordan WD, Jr., Voellinger DC, Fisher WS, et al. A comparison of carotid angioplasty with stenting versus endarterectomy with regional anesthesia. J Vasc Surg. Sep 1998;28(3):397-402; discussion 402-393. PMID 9737448*

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

13. Lewis SC, Warlow CP, Bodenham AR, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. *Lancet*. Dec 20 2008;372(9656):2132-2142. PMID 19041130
14. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med*. Oct 7 2004;351(15):1493-1501. PMID 15470212
15. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. *N Engl J Med*. Apr 10 2008;358(15):1572-1579. PMID 18403765
16. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol*. Oct 2008;7(10):893-902. PMID 18774746
17. Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet*. Oct 7 2006;368(9543):1239-1247. PMID 17027729
18. Naylor AR. SPACE: not the final frontier [Comment]. *Lancet*. Oct 7 2006;368(9543):1215-1216. PMID 17027708
19. Furlan AJ. Carotid-artery stenting--case open or closed? [Editorial]. *N Engl J Med*. Oct 19 2006;355(16):1726-1729. PMID 17050898
20. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med*. Oct 19 2006;355(16):1660-1671. PMID 17050890
21. Arquizan C, Trinquart L, Touboul PJ, et al. Restenosis is more frequent after carotid stenting than after endarterectomy: the EVA-3S study. *Stroke*. Apr 2011;42(4):1015-1020. PMID 21311065
22. Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. *Lancet Neurol*. Oct 2008;7(10):885-892. PMID 18774745
23. Mas JL, Arquizan C, Calvet D, et al. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. *Stroke*. Sep 2014;45(9):2750-2756. PMID 25082808
24. International Carotid Stenting Study Investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. *Lancet*. Mar 20 2010;375(9719):985-997. PMID 20189239
25. Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). *Lancet Neurol*. Apr 2010;9(4):353-362. PMID 20189458
26. Rothwell PM. Carotid stenting: more risky than endarterectomy and often no better than medical treatment alone [Comment]. *Lancet*. Mar 20 2010;375(9719):957-959. PMID 20304225

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

27. Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. *Lancet*. Feb 7 2015;385(9967):529-538. PMID 25453443
28. Altinbas A, Algra A, Brown MM, et al. Effects of carotid endarterectomy or stenting on hemodynamic complications in the International Carotid Stenting Study: a randomized comparison. *Int J Stroke*. Apr 2014;9(3):284-290. PMID 23834300
29. Featherstone RL, Dobson J, Ederle J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): a randomised controlled trial with cost-effectiveness analysis. *Health Technol Assess*. Mar 2016;20(20):1-94. PMID 26979174
30. Hopkins LN, Roubin GS, Chakhtoura EY, et al. The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. *J Stroke Cerebrovasc Dis*. Mar 2010;19(2):153-162. PMID 20189092
31. Silver FL, Mackey A, Clark WM, et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). *Stroke*. Mar 2011;42(3):675-680. PMID 21307169
32. Lal BK, Beach KW, Roubin GS, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. *Lancet Neurol*. Sep 2012;11(9):755-763. PMID 22857850
33. Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. *N Engl J Med*. Mar 17 2016;374(11):1021-1031. PMID 26890472
34. Roffi M, Sievert H, Gray WA, et al. Carotid artery stenting versus surgery: adequate comparisons? *Lancet Neurol*. Apr 2010;9(4):339-341; author reply 341-332. PMID 20189459
35. Nallamotheu BK, Gurm HS, Ting HH, et al. Operator experience and carotid stenting outcomes in Medicare beneficiaries. *JAMA*. Sep 28 2011;306(12):1338-1343. PMID 21954477
36. Gonzales NR, Demaerschalk BM, Voeks JH, et al. Complication rates and center enrollment volume in the carotid revascularization endarterectomy versus stenting trial. *Stroke*. Nov 2014;45(11):3320-3324. PMID 25256180
37. Spence JD, Naylor AR. Endarterectomy, stenting, or neither for asymptomatic carotid-artery stenosis [editorial]. *N Engl J Med*. Mar 17 2016;374(11):1087-1088. PMID 26890473
38. Li FM, Zhong JX, Jiang X, et al. Therapeutic effect of carotid artery stenting versus endarterectomy for patients with high-risk carotid stenosis. *Int J Clin Exp Med*. Oct 2014;7(9):2895-2900. PMID 25356155
39. Kuliha M, Roubec M, Prochazka V, et al. Randomized clinical trial comparing neurological outcomes after carotid endarterectomy or stenting. *Br J Surg*. Feb 2015;102(3):194-201. PMID 25511816
40. Gray WA. Carotid stenting or carotid surgery in average surgical-risk patients: interpreting the conflicting clinical trial data. *Prog Cardiovasc Dis*. Jul-Aug 2011;54(1):14-21. PMID 21722782



<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

41. Woo K, Garg J, Hye RJ, et al. Contemporary results of carotid endarterectomy for asymptomatic carotid stenosis. *Stroke*. May 2010;41(5):975-979. PMID 20339122
42. Barnett HJ, Pelz DM, Lownie SP. Reflections by contrarians on the post-CREST evaluation of carotid stenting for stroke prevention. *Int J Stroke*. Dec 2010;5(6):455-456. PMID 21050401
43. Angioplasty and stenting of the cervical carotid artery with distal embolic protection of the cerebral circulation. *Technol Eval Cent Assess Program Exec Summ*. Feb 2005;19(15):1-4. PMID 15714698
44. Ederle J, Featherstone RL, Brown MM. Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review. *Stroke*. Apr 2009;40(4):1373-1380. PMID 19228850
45. Bangalore S, Kumar S, Wetterslev J, et al. Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. *Arch Neurol*. Feb 2011;68(2):172-184. PMID
46. Murad MH, Shahrour A, Shah ND, et al. A systematic review and meta-analysis of randomized trials of carotid endarterectomy vs stenting. *J Vasc Surg*. Mar 2011;53(3):792-797. PMID 21216556
47. Economopoulos KP, Sergentanis TN, Tsigoulis G, et al. Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes. *Stroke*. Mar 2011;42(3):687-692. PMID 21233476
48. Touze E, Trinquart L, Chatellier G, et al. Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting. *Stroke*. Dec 2009;40(12):e683-693. PMID 19892997
49. Carotid Stenting Trialists Collaboration, Bonati LH, Dobson J, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. *Lancet*. Sep 25 2010;376(9746):1062-1073. PMID 20832852
50. Paraskevas KI, Lazaridis C, Andrews CM, et al. Comparison of cognitive function after carotid artery stenting versus carotid endarterectomy. *Eur J Vasc Endovasc Surg*. Mar 2014;47(3):221-231. PMID 24393665
51. Galyfos G, Sigala F, Karanikola E, et al. Cardiac damage after carotid intervention: a meta-analysis after a decade of randomized trials. *J Anesth*. Dec 2014;28(6):866-872. PMID 24828849
52. Vincent S, Eberg M, Eisenberg MJ, et al. Meta-analysis of randomized controlled trials comparing the long-term outcomes of carotid artery stenting versus endarterectomy. *Circ Cardiovasc Qual Outcomes*. Oct 2015;8(6 Suppl 3):S99-108. PMID 26515216
53. Spangler EL, Goodney PP, Schanzer A, et al. Outcomes of carotid endarterectomy versus stenting in comparable medical risk patients. *J Vasc Surg*. Nov 2014;60(5):1227-1231, 1231 e1221. PMID 24953899
54. Salzler GG, Farber A, Rybin DV, et al. The association of Carotid Revascularization Endarterectomy versus Stent Trial (CREST) and Centers for Medicare and Medicaid Services Carotid Guideline Publication on utilization and outcomes of carotid stenting among "high-risk" patients. *J Vasc Surg*. Jul 2017;66(1):104-111 e101. PMID 28502543

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

55. Lee VH, Brown RD, Jr., Mandrekar JN, et al. Incidence and outcome of cervical artery dissection: a population-based study. *Neurology*. Nov 28 2006;67(10):1809-1812. PMID 17130413

56. Schirmer CM, Atalay B, Malek AM. Endovascular recanalization of symptomatic flow-limiting cervical carotid dissection in an isolated hemisphere. *Neurosurg Focus*. Jun 2011;30(6):E16. PMID 21631217

57. Ohta H, Natarajan SK, Hauck EF, et al. Endovascular stent therapy for extracranial and intracranial carotid artery dissection: single-center experience. *J Neurosurg*. Jul 2011;115(1):91-100. PMID 21417710

58. Asif KS, Lazzaro MA, Tebeb MS, et al. Endovascular reconstruction for progressively worsening carotid artery dissection. *J Neurointerv Surg*. Jan 2015;7(1):32-39. PMID 24391159

59. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery Developed in Collaboration With the American Academy of Neurology and Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol*. Feb 22 2011;57(8):e16-94. PMID 21288679

60. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *Circulation*. Jul 26 2011;124(4):e54-130. PMID 21282504

61. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. *Stroke*. Aug 2011;42(8):e420-463. PMID 21282494

62. Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. *J Vasc Surg*. Sep 2011;54(3):e1-31. PMID 21889701

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

63. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Carotid Artery Stenting (CAG-00085R). 2005; [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=157&NcaName=Carotid+Artery+Stenting+\(1st+Recon\)](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=157&NcaName=Carotid+Artery+Stenting+(1st+Recon)). Accessed March 17, 2020.
64. Hopkins LN, Myla S, Grube E, et al. Carotid artery revascularization in high surgical risk patients with the NexStent and the Filterwire EX/EZ: 1-year results in the CABERNET trial. *Catheter Cardiovasc Interv.* Jun 1 2008;71(7):950-960. PMID 18412236
65. Bonati LH, Lyrer P, Ederle J, et al. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. *Cochrane Database Syst Rev.* Sep 12 2012(9):CD000515. PMID 2297204776.
66. Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.68, Extracranial Carotid Artery Stenting. June 2019.

## X. POLICY HISTORY

[TOP](#)

<b>MP-2.008</b>	<b>CAC 2/25/03</b>
	<b>CAC 12/14/04</b>
	<b>CAC 1/31/06</b>
	<b>CAC 1/30/07</b>
	<b>CAC 11/27/07</b>
	<b>CAC 11/25/08</b>
	<b>CAC 9/29/09 Consensus Review</b>
	<b>CAC 5/25/10 Minor review.</b> Guidelines revised, however no change to coverage. Intracranial percutaneous stenting criteria removed from policy and policy retitled, “Extracranial Angioplasty/Stenting.” FEP PPO variation added to the policy.
	<b>CAC 7/26/11 Consensus Review</b>
	<b>CAC 6/26/12 Adopt BCBSA.</b> Carotid dissection added to policy statement as investigational, and policy statement clarified to read that CAS is investigational in patients who are suitable candidates for CEA. Changed FEP variation to reference the FEP Medical Policy Manual MP-7.01.68 External Carotid Angioplasty/Stenting
	<b>Admin Update Review Complete 7.16.13</b>
	<b>CAC 9/24/13 Consensus review.</b> References updated but no changes to the policy statements. Rationale added.
	<b>12/19/2013-</b> New 2014 Code updates made.
	<b>CAC 7/22/14 Consensus review.</b> No change to policy statements. References updated.
<b>CAC 7/21/15 Consensus review.</b> No changes to the policy statements, Background, rationale, and references updated. Codes reviewed.	

# MEDICAL POLICY



<b>POLICY TITLE</b>	<b>EXTRACRANIAL CAROTID ANGIOPLASTY/STENTING</b>
<b>POLICY NUMBER</b>	<b>MP-2.008</b>

	<b>CAC 7/25/16 Consensus review.</b> No change to policy statements. Background, rationale and references updated. Coding updated.
	<b>Admin update 1/1/17:</b> Product variation section reformatted.
	<b>CAC 9/26/17 Consensus review.</b> Policy statements separated for carotid angioplasty with or without stenting. Policy statements otherwise unchanged. Background, rationale, and references updated. Coding reviewed.
	<b>1/1/18 Admin Update:</b> Medicare variations removed from Commercial Policies.
	<b>6/04/18 Consensus review.</b> Policy statements unchanged. FEP policy title updated. Description/Background, Rationale and Reference sections updated.
	<b>6/14/19 Consensus review.</b> Policy statements unchanged. Background, and Reference sections updated.
	<b>3/17/2020 Consensus review.</b> Policy statement unchanged. References reviewed. Coding updated.

[Top](#)

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.*